Baillie Gifford Amends 10x Genomics Stake as of Dec 29, 2023
Ticker: TXG · Form: SC 13G/A · Filed: Jan 29, 2024 · CIK: 1770787
| Field | Detail |
|---|---|
| Company | 10x Genomics, Inc. (TXG) |
| Form Type | SC 13G/A |
| Filed Date | Jan 29, 2024 |
| Risk Level | low |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: institutional-ownership, amendment, 13G, investor-update
TL;DR
**Baillie Gifford updated their 10x Genomics stake, watch for details on their new position.**
AI Summary
Baillie Gifford & Co, a major investment firm, filed an amended Schedule 13G/A on January 29, 2024, indicating a change in their ownership of 10x Genomics, Inc. Class A Common Stock as of December 29, 2023. This filing, an amendment to a previous disclosure, signals that Baillie Gifford's stake in 10x Genomics has likely shifted, which is important for investors as large institutional movements can influence stock price and reflect a significant investor's updated view on the company's prospects.
Why It Matters
Changes in large institutional holdings can signal shifts in investor confidence and potentially impact stock liquidity and price for 10x Genomics.
Risk Assessment
Risk Level: low — This filing is a routine update on institutional ownership and doesn't inherently present a direct risk, but rather provides transparency.
Analyst Insight
Investors should look for the full details of the amended filing (which would be on the subsequent pages of the actual SEC document, not provided here) to understand the exact change in Baillie Gifford's ownership percentage and share count in 10x Genomics, Inc. This information can help assess institutional confidence.
Key Players & Entities
- Baillie Gifford & Co (company) — the investment firm filing the SC 13G/A
- 10x Genomics, Inc. (company) — the subject company whose Class A Common Stock is being reported
- December 29, 2023 (date) — the date of the event requiring the filing
- January 29, 2024 (date) — the date the SC 13G/A was filed
FAQ
What type of filing is this document?
This document is an SC 13G/A, which is an amendment to a Schedule 13G filing, as stated in the 'FORM TYPE: SC 13G/A' and 'SCHEDULE 13G (Amendment No.2)' sections.
Who is the filer of this SC 13G/A?
The filer of this SC 13G/A is Baillie Gifford & Co, as indicated under the 'FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: BAILLIE GIFFORD & CO' section.
What company's securities are the subject of this filing?
The securities of 10x Genomics, Inc. are the subject of this filing, specifically their Class A Common Stock, as stated under 'SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: 10x Genomics, Inc.' and 'Name of Issuer) Class A Common'.
What was the 'Date of Event Which Requires Filing of this Statement'?
The 'Date of Event Which Requires Filing of this Statement' was December 29, 2023, as explicitly stated in the filing.
Under which rule was this Schedule 13G filed?
This Schedule 13G was filed under Rule 13d-1(b), as indicated by the '[X] Rule 13d-1(b)' checkbox.
Filing Details
This Form SC 13G/A (Form SC 13G/A) was filed with the SEC on January 29, 2024 regarding 10x Genomics, Inc. (TXG).